Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.

Kaseb, Ahmed O; Guan, Yinghui; Gok Yavuz, Betul; Abbas, Alexander R; Lu, Shan; Hasanov, Elshad; Toh, Han Chong; Verret, Wendy; Wang, Yulei

Kaseb, Ahmed O; Guan, Yinghui; Gok Yavuz, Betul; Abbas, Alexander R; Lu, Shan; Hasanov, Elshad; Toh, Han Chong; Verret, Wendy; Wang, Yulei.

Afiliación

Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guan Y; Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.
Gok Yavuz B; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abbas AR; Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.
Lu S; Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.
Hasanov E; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Toh HC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Verret W; Product Development, Genentech Inc, South San Francisco, CA, USA.
Wang Y; Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USA.

J Hepatocell Carcinoma ; 9: 1065-1079, 2022.

Article en En | MEDLINE | ID: mdl-36254201

Palabras clave

HCC; IGF-CTP score; immunotherapy; prognostic biomarker

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Hepatocell Carcinoma Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google